#United States #New York #Pomerantz LLP #Larimar Therapeutics #LCRM

In a significant development for shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR), the Pomerantz Law Firm has initiated an investigation into claims arising from the company’s recent disclosures. This scrutiny focuses on potential securities fraud and other unlawful practices by the firm's executives. On September 29, 2025, Larimar announced data from a long-term study related to its treatment under investigation, Nomlabofusp, for Friedreich's Ataxia, a rare genetic disorder. The data, while presented as "positive," also revealed concerning information: seven participants of the study experienced anaphylaxis, a severe allergic reaction. This alarming revelation was met with a swift negative market response, leading to a sharp decline in Larimar's stock price by $1.72 per share, or an equivalent of 33.66%, closing at $3.38 per share on the same day. Investors are potentially facing losses due to the perceived positive outlook contradicted by serious health risks associated with the treatment. Given these circumstances, Pomerantz LLP encourages affected investors to step forward. As a leading firm in corporate and securities law, Pomerantz has a long-standing history of championing the rights of those adversely affected by corporate misconduct. Founded over 85 years ago by Abraham L. Pomerantz, recognized for pioneering securities class actions, the firm continues to uphold its legacy by pursuing justice for shareholders. Interested parties can contact Danielle Peyton at Pomerantz to learn more about their legal options regarding the potential class-action lawsuit. The firm operates out of several major cities, including New York and Chicago, and boasts a proven track record of securing substantial damages for class members in cases of securities fraud. Consumers and investors alike must remain vigilant in the fast-paced and often turbulent environment of stock market investments. When corporations fail to uphold their fiduciary duties, it is critical for attorneys and law firms like Pomerantz to address these wrongdoings and provide recourse for aggrieved investors. Investors are invited to gather more information about how they can join this investigation and to better understand their rights regarding this matter.